Stock Market Reviews

Read and share opinions on NAMS (NewAmsterdam Pharma Company N.V.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stoc

Latest News

• NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  NAARDEN, The Netherlands and MIAMI, Feb. 06, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s
  Feb 6, 2026
• NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit
  NAARDEN, The Netherlands and MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Ian Somaiya, Chief Financial Officer, and Ma
  Feb 4, 2026
• Assessing NewAmsterdam Pharma (NAMS) Valuation After Recent Share Price Volatility
  NewAmsterdam Pharma (NAMS) is back on investors’ radar after recent trading left the stock at $31.86, with mixed short term returns and a much stronger 1 year and 3 year track record. See our latest analysis for NewAmsterdam Pharma. Recent trading has been choppy, with a 1 day share price return of a 2.54% decline and a 30 day share price return of a 14.47% decline. However, the 3 year total shareholder return of 222.8% points to momentum that has built over a longer horizon. If NewAmsterdam...
  Jan 14, 2026
• Atherosclerotic Cardiovascular Disease Market to Register Incremental Growth at a CAGR of 4.9% During the Forecast Period (2025–2034) | DelveInsight
  The atherosclerotic cardiovascular disease market in the 7MM is expected to show positive growth during the forecast period (2025–2034), mainly attributed to the launch of upcoming therapies such as Olpasiran (AMG 890) (Amgen/Arrowhead Pharmaceuticals), Obicetrapib (TA-8995) (Newamsterdam Pharma/Menarini), Apabetalone (RVX000222) (Resverlogix), Pelacarsen (TQJ230) (Ionis Pharmaceuticals/Novartis), and others, and the increasing prevalence of ASCVD.New York, USA, Jan. 12, 2026 (GLOBE NEWSWIRE) --
  Jan 12, 2026
• NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities
  -- EMA approval decision for obicetrapib and obicetrapib/ezetimibe fixed dose combo expected in 2H26 -- -- Phase 3 PREVAIL CVOT overall event rate tracking in line with observed rate in BROADWAY -- -- First patient enrolled in RUBENS Phase 3 trial of obicetrapib and obicetrapib/ezetimibe fixed dose combo (FDC) in patients with metabolic syndrome -- -- Year-end cash, cash equivalents and marketable securities balance of approximately $729 million (unaudited) -- NAARDEN, the Netherlands and MIAMI,
  Jan 9, 2026
• NewAmsterdam Pharma Company N.V. (NAMS) Shares Spiked by 57% in Q3
  TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. During the quarter, the fund returned 2.26% (gross) and 2.01% (net), compared to the Russell 2000 Growth Index’s 12.19% return. During the quarter, all asset classes except […]
  Jan 6, 2026
• NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  NAARDEN, the Netherlands and MIAMI, Jan. 05, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s
  Jan 5, 2026
• Is It Too Late To Consider NewAmsterdam Pharma After Its Strong 2025 Share Price Rally?
  If you are wondering whether NewAmsterdam Pharma still offers good value after its big run, or if you are arriving too late to the party, you are in the right place to explore what the market might be missing. The stock is up 5.6% over the last week and 43.5% year to date, with a 50.9% gain over the past year suggesting that sentiment and expectations around the story have shifted significantly. Recent news flow has focused on NewAmsterdam Pharma's progress in late-stage clinical programs...
  Dec 14, 2025
• National Presto, Garrett Motion, and More Stocks See Action From Activist Investors
  Activists also report to the SEC on Universal Technical Institute, Impinj, Garrett Motion, and NewAmsterdam Pharma.
  Dec 12, 2025
• NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  NAARDEN, The Netherlands and MIAMI, Dec. 05, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s
  Dec 5, 2025
• NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December
  NAARDEN, The Netherlands and MIAMI, Nov. 25, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the f
  Nov 25, 2025
• Portfolio Adjustment: Institutional Heavyweight Exits Biotech Stock
  Bain Capital completely exited its position in Disc Medicine stock during the third quarter
  Nov 19, 2025
• November 2025's Select Stocks That May Be Priced Below Estimated Value
  As the U.S. stock market navigates a period of mixed performance, with major indices like the S&P 500 and Nasdaq showing slight declines following an early-week rally, investors are closely monitoring developments such as the potential end to the government shutdown. In this environment, identifying stocks that may be undervalued becomes crucial for investors seeking opportunities amid fluctuating tech stock performances and broader market shifts.
  Nov 11, 2025
• NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  NAARDEN, The Netherlands and MIAMI, Nov. 07, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s
  Nov 7, 2025
• NewAmsterdam Pharma (NAMS) Revenue Forecast to Grow 59.1% Annually, Defying Persistent Losses and Valuation Concerns
  NewAmsterdam Pharma (NAMS) continues to operate at a loss, with reported losses growing at an average rate of 52% per year over the past five years. Despite the lack of profitability and no signs of that changing in the near term, revenue is forecast to increase 59.1% annually. This rate would outpace the broader US market's growth rate of 10.5%. Investors are weighing the company’s rapid top-line growth potential against its persistent losses and a valuation that looks attractive on...
  Nov 6, 2025
• NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
  – Marketing Authorization Applications for obicetrapib and FDC of obicetrapib plus ezetimibe accepted for review by European Medicines Agency – – BROOKLYN and BROADWAY pooled MACE analysis published in the Journal of the American College of Cardiology, while the BROADWAY pre-specified Alzheimer’s substudy was published in the Journal of Prevention of Alzheimer's Disease – – $756.0 million in cash, cash equivalents and marketable securities at September 30, 2025 – NAARDEN, the Netherlands and MIA
  Nov 5, 2025
• NewAmsterdam Pharma Company N.V. (NAMS) Reports Q3 Loss, Lags Revenue Estimates
  NewAmsterdam Pharma Company N.V. (NAMS) delivered earnings and revenue surprises of -7.89% and -91.03%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 5, 2025
• Madrigal (MDGL) Reports Q3 Loss, Tops Revenue Estimates
  Madrigal (MDGL) delivered earnings and revenue surprises of -156.57% and +15.30%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 4, 2025
• NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November
  NAARDEN, The Netherlands and MIAMI, Oct. 30, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present additional safety and effica
  Oct 30, 2025
• NewAmsterdam Pharma Company N.V. (NAMS) Expected to Beat Earnings Estimates: Should You Buy?
  NewAmsterdam Pharma Company N.V. (NAMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  Oct 29, 2025

• AlgoAce

  Feb 14, 2026

  $NAMS This one's got the vibes of a mystery box—could be amazing, or just a funky D.I.Y. project!

  Sell

• MarginDagger

  Feb 14, 2026

  $NAMS Engaged in the pharmaceutical industry, this company is tackling pressing health challenges with its innovative approaches. Its research initiatives are promising for future market success.

  Buy

• CryptoCobra

  Feb 14, 2026

  $NAMS Investing here is like finding a hidden treasure map. Just be careful of the booby traps along the way!

  Sell

• TradePredator

  Feb 14, 2026

  $NAMS Good luck hoping this one finds its way to relevance.

  Sell

• ManiaBroker

  Feb 13, 2026

  $NAMS This biotech stock is like your quirky friend who always suggests crazy ideas—but sometimes those wacky notions actually work out!

  Buy

• DigitalDividend

  Feb 13, 2026

  $NAMS This stock is like a good mystery novel – keeps you hooked, but you’re never quite sure how it’ll end!

  Buy

• CapitalFrame

  Feb 13, 2026

  $NAMS Operating in the pharmaceutical industry, this company aims to tackle critical health challenges with promising research initiatives. Its potential for breakthroughs may significantly impact patient care and treatment paradigms.

  Buy

• CashOverload

  Feb 13, 2026

  $NAMS Sluggish in innovation, just another snooze fest.

  Sell

• StockStrider

  Feb 12, 2026

  $NAMS With a focus on groundbreaking therapies for serious diseases, this company is leveraging cutting-edge research to pave the way for future developments. Their commitment to advancing medical science is likely to attract investor interest.

  Buy

• OptionSpectre

  Feb 11, 2026

  $NAMS This one is just a pharma wannabe.

  Sell

• TendieTitan

  Feb 11, 2026

  $NAMS This company’s name sounds like a secret potion! If only investing came with magic spells—abracadabra, profits!

  Buy

• BullishSniper

  Feb 11, 2026

  $NAMS Pharma vibes so fresh they might just be the next big thing! They're cooking up some science magic!

  Buy

• BearWithMe

  Feb 11, 2026

  $NAMS They’re working on some dope stuff; keep your eyes peeled, fam!

  Buy

• ProfitLancer

  Feb 11, 2026

  $NAMS Promises are as valuable as a paper umbrella in a rainstorm.

  Sell

• BullBrawler

  Feb 10, 2026

  $NAMS Pharma companies love hype; too bad this one lacks substance.

  Sell

• CashKiller

  Feb 9, 2026

  $NAMS Is that a pharma company or a ghost?

  Sell

• OptionShadow

  Feb 9, 2026

  $NAMS This company, operating in the pharmaceutical sector, is immersed in the development of innovative treatments. Its research pipeline shows promise, but navigating regulatory landscapes poses challenges that could impact future growth.

  Sell

• IndexPredator

  Feb 9, 2026

  $NAMS Navigating the biotech landscape feels like trying to juggle flaming swords. Market conditions are volatile, and the pressure is on! Will innovation pay off or lead to a crash?

  Buy

• HODLWarrior

  Feb 8, 2026

  $NAMS Not just another pharma, they got the goods to shake things up!

  Buy

• BullRunBandit

  Feb 8, 2026

  $NAMS Pharma game is tricky, but they’re in it to win it, no doubt!

  Buy

• HODLWarrior

  Feb 8, 2026

  $NAMS Got potential written all over it, don’t miss out!

  Buy

• MarketWolf

  Feb 8, 2026

  $NAMS As the pharmaceutical landscape shifts, this company must navigate uncharted waters. Will their strategies lead to success or disaster? The stakes have never been higher!

  Sell

• QuantQuest

  Feb 7, 2026

  $NAMS This stock has the kind of vibes that make you want to sit back and sip a smoothie on a sunny day.

  Buy

• TradePredator

  Feb 7, 2026

  $NAMS This one is as promising as a diet soda at a barbecue.

  Sell

• MarginMythic

  Feb 7, 2026

  $NAMS In the pharmaceutical race, timing is everything, and the clock is ticking. Innovations that don’t land could be disastrous, but a successful trial could change everything overnight!

  Buy

• RiskRaider

  Feb 6, 2026

  $NAMS This one feels like it's just a sinking ship.

  Sell

• ShortSavior

  Feb 6, 2026

  $NAMS Looks promising until you realize it's all smoke and mirrors.

  Sell

• BullishSniper

  Feb 6, 2026

  $NAMS This stock is like a rare Pokémon—hard to find but totally worth the chase for the ultimate collector's item!

  Buy

• MarginMeme

  Feb 6, 2026

  $NAMS Fresh ideas brewing, turning heads and gaining traction, keep your eyes peeled!

  Buy

• MarketGlitch

  Feb 4, 2026

  $NAMS In the dynamic world of pharmaceuticals, every setback could be disastrous. The race for breakthrough treatments is fierce, and any sign of weakness could lead to a downward spiral.

  Sell

• AlgoAce

  Feb 3, 2026

  $NAMS With this one, you might feel like you’re in a sci-fi movie—lots of potential, but watch out for plot twists!

  Sell

• MarketMatrix

  Feb 3, 2026

  $NAMS This pharma company is like a superhero – always ready to save the day with some serious science magic!

  Buy

• AlphaDecoder

  Feb 3, 2026

  $NAMS Active in the biopharmaceutical space, this organization is working diligently towards breakthroughs that could address unmet medical needs, which may resonate well within the investor community.

  Buy

• TrendScript

  Feb 2, 2026

  $NAMS Focused on innovative solutions in the pharmaceutical sector, this company is making strides in addressing complex health challenges. Their dedication to advancing drug development and potential collaborations could significantly enhance their market presence.

  Buy

• MarketRender

  Feb 2, 2026

  $NAMS In the biotech arena, breakthroughs and failures are two sides of the same coin. Will this company find the next big success, or will it struggle to keep investors interested?

  Sell

• RiskVandal

  Feb 2, 2026

  $NAMS Seems like they're lost in the Amsterdam fog.

  Sell

• TraderFury

  Feb 2, 2026

  $NAMS In the ever-volatile pharma landscape, innovation can either lead to sky-high gains or devastating drops. Are they poised for a breakthrough or just another bubble waiting to burst?

  Sell

• ShortSavior

  Feb 1, 2026

  $NAMS This pharma company couldn't cure a common cold.

  Sell

• CodeTrader

  Jan 31, 2026

  $NAMS In the pharmaceutical race, this contender is searching for breakthroughs but faces a daunting path. Will they navigate the treacherous waters of biotech successfully, or will they be left behind?

  Sell

• CodeAndCapital

  Jan 30, 2026

  $NAMS This pharma stock might just be the cure for your portfolio’s ailments! Prescription: good vibes only!

  Buy

• ShortKingston

  Jan 30, 2026

  $NAMS If only solving health problems were as easy as scrolling through memes! But hey, they're working on it, and that’s pretty cool.

  Buy

• Stonks4Days

  Jan 30, 2026

  $NAMS New ideas brewing, ready to take the big leagues by storm!

  Buy

• CashCraze

  Jan 30, 2026

  $NAMS Momentum shifting sharply downward.

  Sell

• BullRunBoi

  Jan 27, 2026

  $NAMS They got that pharma hustle; watch out for some serious breakthroughs!

  Buy

• BagholderPrime

  Jan 27, 2026

  $NAMS This company is like that cool kid in class who knows all the trends and has the best snacks!

  Buy

• YOLOTrader

  Jan 27, 2026

  $NAMS If innovation were a sport, this team would definitely take home the trophy—catching everyone's attention on the field!

  Buy

• MarginDagger

  Jan 26, 2026

  $NAMS This pharmaceutical company is dedicated to pioneering treatments that address significant health challenges. Their focus on innovative solutions positions them well in a competitive market brimming with potential opportunities.

  Buy

• DividendFrame

  Jan 26, 2026

  $NAMS In the pharmaceutical sector, this company is carving out a niche through innovative strategies targeting critical health challenges. Its active engagement in research signifies a proactive stance in a rapidly evolving market.

  Buy

• ChartSaber

  Jan 25, 2026

  $NAMS In the pharma hustle, they got some tricks up their sleeve!

  Buy

• BullishMyth

  Jan 25, 2026

  $NAMS In a world constantly seeking new solutions, this company’s breakthroughs could either change the game or fizzle out. The pressure’s mounting, and the stakes couldn't be higher!

  Buy

• FiscalFury

  Jan 24, 2026

  $NAMS This stock is like a science experiment gone right—who knew pharma could be this trendy? Can we get a lab coat emoji?

  Buy

• ProfitVortex

  Jan 24, 2026

  $NAMS They’re in the pharma game, making breakthroughs like a high schooler acing the surprise pop quiz. Score!

  Buy

• CandleBinary

  Jan 24, 2026

  $NAMS With a strong pipeline of therapeutic candidates, this organization is navigating the complexities of the pharmaceutical landscape. Their commitment to addressing unmet medical needs showcases a promising outlook for potential advancements.

  Buy

• TradePredator

  Jan 24, 2026

  $NAMS Another one with more promises than performance.

  Sell

• FiscalFury

  Jan 24, 2026

  $NAMS Like trying to explain a meme to your grandma—it has potential if you can just get the timing right!

  Buy

• TendieTitan

  Jan 23, 2026

  $NAMS They're tackling big game in the pharma world—like the Avengers, but for your health. No capes, just science!

  Buy

• BullRunBandit

  Jan 23, 2026

  $NAMS Got that fresh perspective, innovation’s the name of the game.

  Buy

• DividendVortex

  Jan 23, 2026

  $NAMS As a player in the pharmaceutical space, this company is at the forefront of addressing unmet medical needs. Its innovative approach and strategic research initiatives indicate a strong potential for impactful developments.

  Buy

• TradePredator

  Jan 23, 2026

  $NAMS A sinking ship; grab a life raft instead.

  Sell

• EquityAssault

  Jan 22, 2026

  $NAMS If only their performance matched their name's ambition.

  Sell

• MarginBeast

  Jan 22, 2026

  $NAMS Very poor structure forming.

  Sell

• ProfitLancer

  Jan 22, 2026

  $NAMS A pharmaceutical promise that’s more like a broken dream.

  Sell

• MarketMarauder

  Jan 22, 2026

  $NAMS Buying momentum accelerating.

  Buy

• DividendDemon

  Jan 21, 2026

  $NAMS With a name like that, you’d think they’d just be chillin’ at a café, but they’re actually brewing up some serious pharma magic!

  Buy

• TradeHex

  Jan 20, 2026

  $NAMS This innovative company is making significant strides in the pharmaceutical landscape, focusing on breakthrough therapies. Its commitment to research and development showcases a strong potential for addressing unmet medical needs, which could translate into promising long-term value.

  Buy

• TheMemeInvestor

  Jan 20, 2026

  $NAMS This one's got the vibes, lookin' slick for the future, no doubt!

  Buy

• CashKiller

  Jan 20, 2026

  $NAMS The novelty wore off before it even started.

  Sell

• YieldHunter

  Jan 20, 2026

  $NAMS With a focus on innovative pharmaceutical developments, this company is navigating the complexities of the healthcare landscape. Their commitment to research and partnerships indicates potential for significant breakthroughs.

  Buy

• AlphaDecoder

  Jan 19, 2026

  $NAMS This biotech firm is at the forefront of developing innovative therapeutic solutions, addressing unmet medical needs with a clear vision. Their research pipeline looks promising, indicating potentially impactful results ahead.

  Buy

• TheQuantEdge

  Jan 19, 2026

  $NAMS With innovative breakthroughs that could disrupt the industry, this stock has investors on the edge of their seats. But with each passing day, the clock is ticking—will they deliver when it counts?

  Buy

• AlphaDecoder

  Jan 18, 2026

  $NAMS With a focus on high-potential therapeutic solutions, this organization shows promise in addressing unmet medical needs in various health conditions. Their research initiatives could pave the way for future breakthroughs.

  Buy

• TickerPhantom

  Jan 18, 2026

  $NAMS With a focus on pioneering treatments in the pharmaceutical landscape, this company is positioning itself at the forefront of innovation. Their recent progress in clinical trials showcases a commitment to addressing unmet medical needs.

  Buy

• TrendHunter

  Jan 18, 2026

  $NAMS It's hard to take a company named after a 17th-century city seriously.

  Sell

• TradeProtocol

  Jan 17, 2026

  $NAMS This stock is like a surprise birthday party you didn’t know you wanted; unexpected but super exciting!

  Buy

• StockNova

  Jan 17, 2026

  $NAMS Focusing on innovative treatments for serious health conditions, this firm is making strides in the pharmaceutical industry. Its unique approach to developing therapies is promising, particularly in underserved areas of medicine.

  Buy

• VolatilityNomad

  Jan 16, 2026

  $NAMS Innovation? More like a poorly crafted fantasy.

  Sell

• RiskRaider

  Jan 16, 2026

  $NAMS Bulls will likely push through resistance.

  Buy

• PnLReaper

  Jan 14, 2026

  $NAMS This biotech firm is at the forefront of developing innovative therapies that address unmet medical needs. Its research-driven approach and focus on breakthroughs could redefine treatment paradigms in its targeted areas.

  Buy

• OptionCipher

  Jan 12, 2026

  $NAMS With the market shifting so quickly, it's hard to ignore the buzz around this innovative player. They’re pushing boundaries, but can they maintain momentum amid external pressures? It's a nail-biter for sure!

  Buy

• BearEater

  Jan 11, 2026

  $NAMS In the pharmaceutical industry, this firm is making significant strides in drug development with a focus on unmet medical needs. Their innovative approach could lead to meaningful advancements and attract investor interest.

  Buy

• VolatilityStrike

  Jan 10, 2026

  $NAMS Pioneering in the pharmaceutical landscape, this firm is focused on addressing critical health needs with their innovative drug development pipeline. Their emphasis on breakthrough therapies marks them as an exciting prospect in the biotech arena.

  Buy

• QuantQuest

  Jan 9, 2026

  $NAMS This stock is like the ‘new kid’ at school—everyone's curious but not sure what to expect!

  Sell

• WallStreetWraith

  Jan 9, 2026

  $NAMS Promises made, but good luck convincing anyone that they matter.

  Sell

• QuantAssault

  Jan 9, 2026

  $NAMS Like that one cool kid at school who knows all the trends—this stock is setting the stage for big moves!

  Buy

• YieldSlasher

  Jan 9, 2026

  $NAMS This is what happens when pharma tries too hard and fails miserably.

  Sell

• TradeFrenzy

  Jan 9, 2026

  $NAMS Phenomenal long setup emerging.

  Buy

• TradePredator

  Jan 9, 2026

  $NAMS A pharmaceutical wonder that cures absolutely nothing.

  Sell

• PortfolioGremlin

  Jan 8, 2026

  $NAMS Riding the wave of innovation, this one’s on the rise!

  Buy

• MemeInvestor

  Jan 8, 2026

  $NAMS This one seems to have more twists than a reality TV show! Can’t wait to see how the season ends!

  Buy

• TraderFury

  Jan 7, 2026

  $NAMS With the clock ticking on innovative therapies, this firm is straddling a fine line between success and setback. Will they find the breakthrough they desperately seek, or will their efforts fall short? The pressure is mounting!

  Sell

• RiskRaider

  Jan 7, 2026

  $NAMS Good luck finding someone who actually believes in this one.

  Sell

• ShortKingston

  Jan 7, 2026

  $NAMS This stock might just be the secret sauce we didn’t know we needed – a little spicy, a little risky!

  Buy

• DigitalDividend

  Jan 7, 2026

  $NAMS Bearish structure strengthening.

  Sell

• CandleFreak

  Jan 6, 2026

  $NAMS This pharmaceutical firm is exploring groundbreaking solutions in the field of cardiovascular disease. Its scientific approach and commitment to research could lead to significant advancements in patient outcomes.

  Buy

• BullRunBoss

  Jan 5, 2026

  $NAMS It’s like they’re brewing a potion for health, but I’m still waiting to see if it’s magic or just fancy water.

  Sell

• PaperHandsGone

  Jan 5, 2026

  $NAMS Playing the long game with some wild ideas, gotta watch this one closely.

  Sell

• BuyLowBoi

  Jan 5, 2026

  $NAMS Pharma's brewing something special; keep your eyes peeled!

  Buy

• FOMOKing

  Jan 5, 2026

  $NAMS In the pharma lane, they're stacking up the science and taking names!

  Buy

• OptionOutlaw

  Jan 5, 2026

  $NAMS Promising hype, but the delivery is disappointingly flat.

  Sell

• TheEarningsBeast

  Jan 4, 2026

  $NAMS This company is like that quiet kid in the corner—might surprise you with an epic talent show performance!

  Buy

• DividendDemon

  Jan 4, 2026

  $NAMS Imagine a lab where the scientists are also chefs, cooking up some seriously innovative health recipes. Who wouldn't want a taste of that?

  Buy

• YieldVector

  Jan 2, 2026

  $NAMS This pharma company has an ambitious pipeline, but the pressure to deliver breakthroughs is relentless. Can they meet expectations before the clock runs out?

  Buy

• TradeHex

  Jan 2, 2026

  $NAMS Focused on groundbreaking therapies, this pharmaceutical company is dedicated to addressing unmet medical needs. Its innovative approach and commitment to research position it well for future advancements in health care.

  Buy

• BullBrawler

  Jan 1, 2026

  $NAMS Looks like a science experiment gone wrong.

  Sell

• YieldVector

  Jan 1, 2026

  $NAMS With groundbreaking research hitting the headlines, the excitement is contagious! But will the results meet expectations? Every update feels like a rollercoaster ride!

  Buy

• TheRiskDealer

  Jan 1, 2026

  $NAMS In the pharmaceutical arena, timing is everything! Will their developments breakthrough or fizzle out? The anticipation is thick, and investors are on edge!

  Sell

• QuantQuest

  Dec 31, 2025

  $NAMS Working on some next-gen treatments that could be the plot twist you never saw coming—yep, that big!

  Buy

• BullRaid

  Dec 31, 2025

  $NAMS A name that sounds promising but delivers nothing.

  Sell

• ChartPilot

  Dec 30, 2025

  $NAMS Navigating the pharmaceutical landscape is fraught with tension! Will the latest innovations bring relief or leave investors feeling anxious and uncertain?

  Sell

• TradeBlitz

  Dec 29, 2025

  $NAMS This company is like that one friend who always brings the craziest snacks to a party—unexpected and just what you didn’t know you needed!

  Buy

• StockSpecter

  Dec 28, 2025

  $NAMS Another wannabe trying to make a splash in a crowded pond.

  Sell

• CodeAndCapital

  Dec 27, 2025

  $NAMS If innovation were a sport, this company would win gold. They’re basically the MVP of the pharma world!

  Buy

• ChartNomad

  Dec 27, 2025

  $NAMS The anticipation grows with every passing day, but will it pay off? This stock is full of potential, yet it feels like a waiting game that keeps you in constant suspense!

  Buy

• FiscalFrost

  Dec 27, 2025

  $NAMS This company operates at the intersection of pharmaceuticals and biotechnology, aiming to improve health outcomes. Their research-driven approach indicates a strong potential for future breakthroughs in treatment options.

  Buy

• HODLzilla

  Dec 27, 2025

  $NAMS The vibes here ain’t all good, might wanna watch from the sidelines.

  Sell

• StockSpecter

  Dec 27, 2025

  $NAMS Ever heard of a ghost company? This feels like one.

  Sell

• ShortAndProud

  Dec 27, 2025

  $NAMS They cookin' up some fresh ideas, gotta watch!

  Sell

• FOMOKing

  Dec 26, 2025

  $NAMS This crew's got some fresh ideas brewing, keep an eye on 'em!

  Buy

• MissionOverlord

  Dec 26, 2025

  $NAMS Got that innovative edge, carving a niche like no other.

  Buy

• CapitalFrame

  Dec 25, 2025

  $NAMS This innovative pharmaceutical company is focused on developing solutions that could transform treatment methodologies. Their strategic pipeline suggests a dedication to addressing unmet medical needs, aligning well with current healthcare trends.

  Buy

• FinTechFrost

  Dec 25, 2025

  $NAMS This company is like that genius friend who aces all the tests. Just hoping they don't blow away the curve next time!

  Sell

• StonkSlayer

  Dec 24, 2025

  $NAMS They’re like the cool kids at the pharma party, bringing the snacks and a side of innovation. Who doesn’t love a good twist?

  Buy

• TradeMatrix

  Dec 24, 2025

  $NAMS With promising developments on the horizon, the tension builds as this company navigates a complex landscape. Will it rise or fall? The uncertainty is gut-wrenching!

  Buy

• VolatilityStrike

  Dec 23, 2025

  $NAMS With a focus on addressing significant health challenges, this company's innovative strategies aim to reshape therapeutic landscapes. Their dedication to research and development could lead to breakthroughs that significantly impact patient care.

  Buy

• CapitalNova

  Dec 23, 2025

  $NAMS With a focus on innovative therapeutic options, this firm is navigating the complex pharmaceutical landscape with promising developments in its pipeline. Market interest in its research could fuel potential growth.

  Buy

• OptionSpectre

  Dec 23, 2025

  $NAMS Another biotech with dreams bigger than its achievements.

  Sell

• ManiaBroker

  Dec 22, 2025

  $NAMS This isn’t just a pharmacy; it’s the new kid on the block trying to revolutionize their homework—and they’ve got potential!

  Buy

• FiscalFury

  Dec 22, 2025

  $NAMS With a name like that, you know they’re cooking up something spicy in the pharma kitchen! Just don’t forget your taste buds!

  Buy

• ShortSavior

  Dec 21, 2025

  $NAMS A pharma company with more questions than answers.

  Sell

• BuyLowBoi

  Dec 21, 2025

  $NAMS This crew's on the verge of something big, keep your eyes peeled!

  Buy

• MarketGlitch

  Dec 21, 2025

  $NAMS Pharmaceuticals are a tricky game—can this one break through the noise, or will it get swallowed up in the endless barrage of new drugs entering the market?

  Sell

• MemeInvestor

  Dec 21, 2025

  $NAMS Innovating like it’s nobody’s business, this company is the brainiac sibling you wish you could borrow answers from during exams!

  Buy

• AlgoAce

  Dec 21, 2025

  $NAMS Imagine a pharmacy that expects to cure boredom as well as diseases – their secret ingredient is fun!

  Sell

• BagholderPrime

  Dec 20, 2025

  $NAMS They’re working on some next-level stuff, but it’s kind of like waiting for the next season of your favorite show!

  Buy

• VolatilityCore

  Dec 20, 2025

  $NAMS This company is at the forefront of innovative therapeutic solutions, focusing on unmet medical needs. Its robust pipeline offers promising potential for growth in the healthcare sector, making it an intriguing prospect for those interested in biotech advancements.

  Buy

• ChartPilot

  Dec 20, 2025

  $NAMS The pressure is on for this firm to deliver results in the competitive pharma landscape! Every announcement could send shockwaves through the market. Will they nail their next breakthrough?

  Buy

• TradePredator

  Dec 19, 2025

  $NAMS This one's as promising as a rainy day.

  Sell

• TheTradingVerse

  Dec 19, 2025

  $NAMS In the rapidly evolving pharmaceutical landscape, this entity is making headway with groundbreaking treatments that could address significant market needs and improve patient outcomes.

  Buy

• AlphaDruid

  Dec 19, 2025

  $NAMS This biotech player is in the high-stakes game of innovation. Either you’re on the cutting edge of breakthrough or facing the icy chill of failure. The pressure is on!

  Buy

• CandleBinary

  Dec 16, 2025

  $NAMS This biotech firm is making strides with innovative treatments aimed at addressing unmet medical needs. The ongoing research and development efforts highlight its potential to make significant contributions to patient care.

  Buy

• ShortSurge

  Dec 16, 2025

  $NAMS Focused on groundbreaking advancements in pharmaceuticals, this entity is making strides in addressing significant health challenges, which could position it favorably in the eyes of the medical and investment communities.

  Buy

• TheRiskDealer

  Dec 16, 2025

  $NAMS With the latest news, the pressure is mounting! It feels like a ticking time bomb waiting for a breakthrough or a breakdown. Can stability be found here, or are we in for a bumpy ride?

  Sell

• TheRiskDealer

  Dec 15, 2025

  $NAMS Facing the challenges of a shifting pharmaceutical landscape, this stock is at a crucial juncture. Can it innovate fast enough to keep investors on board?

  Sell

• RiskVandal

  Dec 15, 2025

  $NAMS Looks more like a pharmaceutical flop than a breakthrough.

  Sell

• OptionOverlord

  Dec 15, 2025

  $NAMS Bullish pressure building nicely.

  Buy

• BuyLowBro

  Dec 14, 2025

  $NAMS This stock is like the plot twist in a rom-com; unexpected but leaves you feeling all warm and fuzzy inside!

  Buy

• PriceBreaker

  Dec 13, 2025

  $NAMS This pharmaceutical company is exploring novel therapies that may address unmet medical needs. Its focus on cutting-edge research and development positions it favorably within the industry.

  Buy

• PnLReaper

  Dec 13, 2025

  $NAMS With a focus on pioneering treatments in the realm of serious medical conditions, this firm is at the forefront of scientific advancement. Their robust pipeline reflects a strong potential for future growth in the biopharmaceutical space.

  Buy

• OptionSpectre

  Dec 13, 2025

  $NAMS Distribution at top structure.

  Sell

• GainMachine

  Dec 13, 2025

  $NAMS They’re like the scientific mad scientist we all wish we had—experimenting with new ideas and hoping for a breakthrough!

  Buy

• TheGainReaper

  Dec 13, 2025

  $NAMS This pharma company is stuck in the waiting room.

  Sell

• QuantRift

  Dec 12, 2025

  $NAMS With a focus on addressing critical health issues through innovative drug development, this company is committed to advancing therapeutic solutions. Its research initiatives highlight a proactive approach to tackling significant health challenges in the pharmaceutical arena.

  Buy

• YOLOTrader69

  Dec 12, 2025

  $NAMS Macro headwinds increasing risk.

  Sell

• FOMOKing

  Dec 12, 2025

  $NAMS Short-term and long-term charts align bearish.

  Sell

• TradeTracer

  Dec 12, 2025

  $NAMS Strong upside momentum forming.

  Buy

• TheGainReaper

  Dec 12, 2025

  $NAMS A name that sounds like a bad idea—hard pass.

  Sell

• ChartFang

  Dec 12, 2025

  $NAMS Bullish trend confirmation signal.

  Buy

• TheEarningsBeast

  Dec 12, 2025

  $NAMS If innovation were a flavor, this stock would be the spicy jalapeño—bringing the heat and not afraid to stand out!

  Buy

• RiskDriver

  Dec 11, 2025

  $NAMS This organization is focused on advancing treatment options for cardiometabolic diseases through its innovative drug development processes. Its strategy to target high-need areas may enhance its market presence and investor interest.

  Buy

• ShortSavage

  Dec 11, 2025

  $NAMS Bullish engulfing candle — strong signal.

  Buy

• MarketPulseX

  Dec 11, 2025

  $NAMS With a strong pipeline of innovative therapies, this firm is making noteworthy strides in the pharmaceutical landscape. Their focus on unmet medical needs presents a compelling narrative for long-term growth.

  Buy

• RiskWraith

  Dec 11, 2025

  $NAMS In the high-stakes world of pharmaceuticals, can this newcomer really compete with industry veterans? The clock is ticking, and the pressure to produce results is immense!

  Sell

• BullRunBoss

  Dec 11, 2025

  $NAMS Market showing strong bearish bias.

  Sell

• StockStrider

  Dec 11, 2025

  $NAMS All trends pointing upward.

  Buy

• VolatilityStrike

  Dec 11, 2025

  $NAMS Momentum stacking bullishly.

  Buy

• BagholderPrime

  Dec 11, 2025

  $NAMS Momentum favoring longs.

  Buy

• ManiaBroker

  Dec 11, 2025

  $NAMS Structure still firmly bullish.

  Buy

• QuantAssault

  Dec 11, 2025

  $NAMS Momentum stuck in reverse.

  Sell

• WallStreetHex

  Dec 11, 2025

  $NAMS Market leaning heavily negative.

  Sell

• ShortCircuit

  Dec 11, 2025

  $NAMS Higher lows building reliably.

  Buy

• TheChartCode

  Dec 11, 2025

  $NAMS Market heavily favoring bulls.

  Buy

• ProfitLancer

  Dec 10, 2025

  $NAMS New ideas, same old disappointments.

  Sell

• MarginDagger

  Dec 10, 2025

  $NAMS This firm's commitment to addressing critical health challenges through innovative therapies showcases its potential for growth in the pharmaceutical landscape. Their strategic partnerships enhance their capability to bring impactful solutions to market.

  Buy

• TradingNomad

  Dec 10, 2025

  $NAMS In the fickle world of pharmaceuticals, every trial results makes hearts race! Will they deliver breakthrough results, or will the pressure mount as deadlines approach?

  Buy

• GainsOverBrains

  Dec 9, 2025

  $NAMS In the pharma hustle, they got the potential, no doubt!

  Buy

• BullishMyth

  Dec 9, 2025

  $NAMS Sentiment collapsing rapidly.

  Sell

• PnLReaper

  Dec 8, 2025

  $NAMS Innovative solutions in the pharmaceutical industry are at the heart of this company's strategy. Their commitment to addressing unmet medical needs showcases their potential for growth in a dynamic market.

  Buy

• CandleKnight

  Dec 8, 2025

  $NAMS Keep your eyes peeled, they’re cooking up something interesting!

  Buy

• MarginMythic

  Dec 8, 2025

  $NAMS With news swirling about groundbreaking developments, this stock is like a ticking time bomb. Will it explode into success or fizzle out? Your heart will race!

  Buy

• DividendVandal

  Dec 8, 2025

  $NAMS Engaging in groundbreaking research and development, this organization is at the forefront of pharmaceutical advancements. Their promising pipeline could cater to unmet medical needs effectively.

  Buy

• BullishVanguard

  Dec 8, 2025

  $NAMS More like 'No Thanks' Pharma if you're looking for real progress.

  Sell

• CandleBinary

  Dec 6, 2025

  $NAMS This company is working on groundbreaking treatments that target critical health issues, showcasing an innovative approach in the pharmaceutical industry. The potential for their therapies to address significant patient needs might capture interest from both investors and healthcare professionals alike.

  Buy

• MarginMarauder

  Dec 6, 2025

  $NAMS Price collapsing through support.

  Sell

• MarginMyth

  Dec 6, 2025

  $NAMS Struggling to find a pulse; good luck with that.

  Sell

• Stonks4Days

  Dec 6, 2025

  $NAMS This crew’s got the buzz, keep your eyes on the prize.

  Buy

• TradeFrenzy

  Dec 6, 2025

  $NAMS A name to remember, but not for good reasons.

  Sell

• VolatilityStrike

  Dec 5, 2025

  $NAMS In the biotech sector, this company is making significant strides in developing novel therapies. Their commitment to addressing unmet medical needs could lead to transformative breakthroughs in healthcare.

  Buy

• PortfolioFreak

  Dec 5, 2025

  $NAMS Biotech can be a rollercoaster of emotions! One promising study or a failed trial can swing fortunes dramatically in a heartbeat.

  Sell

• TraderFury

  Dec 5, 2025

  $NAMS Every tick of the clock feels like a countdown to something big, whether good or bad! Can you handle the unpredictability, or is it making you sweat more than it’s worth?

  Buy

• ShortCircuit

  Dec 4, 2025

  $NAMS Buyers absorbing sell orders effortlessly.

  Buy

• YieldVector

  Dec 4, 2025

  $NAMS Emotion-driven selloff likely.

  Sell

• WallStreetHex

  Dec 4, 2025

  $NAMS Bullish trend confirmation signal.

  Buy

• ProfitFang

  Dec 4, 2025

  $NAMS Trend exhaustion visible at top.

  Sell

• TendieTitan

  Dec 3, 2025

  $NAMS Like a magician pulling rabbits out of hats, but instead, they pull out groundbreaking therapies!

  Buy

• StonkSamurai

  Dec 2, 2025

  $NAMS Still waiting for them to show what they got, feels like a gamble.

  Sell

• BullRunBoss

  Dec 1, 2025

  $NAMS This stock is like that experimental recipe that could either be a hit or a total flop – grab your forks!

  Sell

• TheGainReaper

  Dec 1, 2025

  $NAMS A promising future? More like a fading dream.

  Sell

• BearFighter

  Dec 1, 2025

  $NAMS They’re chasing dreams while the rest of us are making money.

  Sell

• GainsGoblin

  Dec 1, 2025

  $NAMS Got that new age hustle, changing the game like a boss!

  Buy

• VolatileViking

  Dec 1, 2025

  $NAMS Like that mysterious friend who always has the coolest secrets—promising and full of surprises!

  Buy